Jim Chopas is the CEO of Apellis Pharmaceuticals, having taken on his role in August 2021. He has a solid academic foundation with a B.A. from the University of Massachusetts and an M.S. from Bentley University. Before leading Apellis, he...

Jim Chopas is the CEO of Apellis Pharmaceuticals, having taken on his role in August 2021. He has a solid academic foundation with a B.A. from the University of Massachusetts and an M.S. from Bentley University. Before leading Apellis, he held several key financial positions, including Vice President and Chief Accounting Officer at Radius Health, Inc., which shows he has extensive experience in the biopharmaceutical sector. His work has focused on improving financial strategies and managing corporate finances efficiently. Jim's analytical skills are also reflected in his compensation structure, which is linked to performance metrics like revenue growth and successful product launches. In 2023, he earned about $475,000, showing a commitment to aligning his goals with the company's success. Under his leadership, Apellis Pharmaceuticals aims to innovate in the medical field, especially in treatments for conditions like geographic atrophy. Outside of his work, Jim has shown a tendency to prioritize a collaborative work environment, positioning the company for continued growth in a competitive market.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Apellis Pharmaceuticals, Inc. CEOs

A

Jim Chopas

CEO of Apellis Pharmaceuticals, Inc.

Education

B.A. from University of Massachusetts; M.S. from Bentley University

Field of Expertise

Finance & Banking - Finance

Sector of Economy

Healthcare

CEO of Apellis Pharmaceuticals, Inc. for

3 years 9 months (Aug 2021 - Present)

Previous Experience

Vice President, Principal Financial Officer, Principal Accounting Officer and Treasurer of Radius Health, Inc.

Rivals

Competitors/colleagues of Jim Chopas

Holdings

See how much did Jim Chopas make over time.

Jim Chopas holds a significant number of shares in Apellis Pharmaceuticals, specifically stock in APLS. While the value of these holdings fluctuates with market trends, they represent a substantial part of his financial profile. In 2021, he was integral to...

Jim Chopas holds a significant number of shares in Apellis Pharmaceuticals, specifically stock in APLS. While the value of these holdings fluctuates with market trends, they represent a substantial part of his financial profile. In 2021, he was integral to guiding the company's financial maneuvers, and his stake in APLS reflects his vested interest in the company’s growth and success. During 2022, he saw his holdings rise in tandem with the company's promising business moves. By 2023, there was a reduction in shares as part of his financial strategy, but publicly available information isn't clear on the current number he holds. This demonstrates his ongoing commitment to being a significant shareholder and risk-taker in the company's future initiatives.

Loading...

Total Stock Sold

$271.85K

APLS

$271.85K

6,128 APLS shares

What if they kept their stock?

If Jim Chopas didn't sell their stock, today they would have:
Extra APLS6,128 shares worth $196.52K.
This is -27.71% and $75.33K less than what they got when they sold the stock.

Insider Trading

See recent insider trades of Jim Chopas.

APLS

$33.35K

APLS at $30.43/share

Jan 22, 2025

Sale

APLS

12,591 shares

APLS

Jan 17, 2025

Received

APLS

$21.42K

APLS at $29.96/share

Jan 17, 2025

Sale

APLS

$22.47K

APLS at $28.70/share

Jan 13, 2025

Sale

APLS

$6.95K

APLS at $36.21/share

Sep 16, 2024

Sale

APLS

$21.72K

APLS at $39.49/share

Sep 3, 2024

Sale

APLS

$10.39K

APLS at $56.46/share

Mar 15, 2024

Sale

APLS

$68.96K

APLS at $65.00/share

Jan 22, 2024

Sale

APLS

8,312 shares

APLS

Jan 16, 2024

Received

APLS

$57.72K

APLS at $66.81/share

Jan 16, 2024

Sale

Compensation History

See how much did Jim Chopas make over time.

In 2023, Jim Chopas received total compensation of $475,000 from Apellis Pharmaceuticals. This amount includes his salary of $350,000, a performance-based bonus of $50,000, and vested stock worth $150,000. The bonus structure incentivizes him to meet key performance metrics tied to the company’s overall growth and success. Just a year prior, in 2022, his total compensation was about $1.225 million, which highlights a significant drop possibly due to changing company priorities or financial adjustments. Jim's compensation plan is designed to align his interests closely with those of the shareholders, ensuring he is focused on the company's long-term performance. His previous roles at Radius Health and KBI Biopharma inform his approach to financial leadership and accountability within Apellis.

Year

2023

Total Compensation

$575.00K

Salary

$350.00K

Board Justification

The compensation philosophy is designed to align the CEO's interests with those of shareholders, focusing on performance-based incentives and retention strategies.

Bonus

$50.00K

Board Justification

The bonus is based on the company's performance metrics and individual contributions during the fiscal year 2023, paid in cash.

Other

$25.00K

Board Justification

Other compensation includes health benefits, retirement contributions, and other perquisites provided to the CEO.

Restricted Stock

$150.00K(10K RSU)

Board Justification

The vested stock consists of restricted stock units that were granted in prior years and vested in 2023, reflecting the company's stock performance and retention strategy.

Performance Metrics

Performance metrics include revenue growth, product launch success, and overall company financial health.

Other Apellis Pharmaceuticals, Inc. CEOs

Here are other CEOs of Apellis Pharmaceuticals, Inc.

Caroline Baumal, M.D.

CEO of Apellis Pharmaceuticals, Inc.

January 2023 - Present